Steen Kølvraa

Steen Kølvraa

Auto-generated profile, based on publicly available information

Steen Kølvraa

Department of Clinical Genetics, Vejle Hospital, Vejle, Denmark

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2011 in Cancer Genetics
Verified
Journal Article
Closed access
TDThomas Dyrsø
Thomas Dyrsø
JLJian Li
Jian Li
KWKai Wang
Kai Wang
JLJan Lindebjerg
Jan Lindebjerg
SKSteen Kølvraa
Steen Kølvraa
DCDorthe G. Crüger
Dorthe G. Crüger

28 June 2010 in Cancers
Verified
Journal Article
Open access
PDF file
THTorben Hansen
Torben Hansen
KSKaren-Lise G. Spindler
Karen-Lise G. Spindler
RARikke Andersen
Rikke Andersen
JLJan Lindebjerg
Jan Lindebjerg
SKSteen Kølvraa
Steen Kølvraa
Anders JakobsenAnders Jakobsen
Anders Jakobsen
New prognostic markers in patients with colorectal cancer (CRC) are a prerequisite for individualized treatment. Prognostic importance of single nucleotide polymorphisms (SNPs) in the vascular endothelial growth factor A (VEGF-A) gene has been proposed. The objective of the present study was to investigate the prognostic importance of haplotypes in the VEGF-A gene in patients with CRC. The study included 486 patients surgically resected for stage II and III CRC, divided into two independent cohorts. Three SNPs in the VEGF-A gene were analyzed by polymerase chain reaction. Haplotypes were estimated using the PHASE program. The prognostic influence was evaluated using Kaplan-Meir plots and log rank tests. Cox regression method was used to analyze the independent prognostic importance of different markers. All three SNPs were significantly related to survival. A haplotype combination, responsible for this effect, was present in approximately 30% of the patients and demonstrated a significant relationship with poor survival, and it remained an independent prognostic marker after multivariate analysis, hazard ratio 2.46 (95% confidence interval 1.49–4.06), p < 0.001. Validation was provided by consistent findings in a second and independent cohort. Haplotype combinations call for further investigation.